Icatibant Acts as a Balanced Ligand of MRGPRX2 in Human Skin Mast Cells
Open Access
- 25 August 2025
- journal article
- research article
- Published by MDPI AG in Biomolecules
- Vol. 15 (9) , 1224
Abstract
MRGPRX2 (Mas-related G protein-coupled receptor member X2) is implicated in mast cell (MC)-driven disorders due to its ability to bind diverse ligands, which may be G-protein-biased or balanced, with the latter activating both G-proteins and the β-arrestin pathway. Icatibant, a peptide drug, produces injection-site reactions in most patients and is used experimentally to probe MRGPRX2 function in skin tests. While reported to be G-protein-biased, it is unknown how skin MCs respond to icatibant, although these are the primary target cells during therapy. We therefore compared responses to icatibant with those induced by the balanced agonist substance P (SP) in skin MCs. Degranulation and desensitization were assessed via β-hexosaminidase release, receptor internalization by flow cytometry, and downstream signaling by immunoblotting. Skin MCs degranulated in response to SP and icatibant, relying on Gi proteins and calcium channels; Gq and PI3K (Phosphoinositide 3-kinase) contributed more strongly to exocytosis following icatibant, while JNK (c-Jun n-terminal kinase) was more relevant for SP. Both agonists activated ERK, PI3K/AKT, and (weakly) p38. Surprisingly, and in contrast to the LAD2 (Laboratory of Allergic Diseases 2 mast cell line) MC line, icatibant was at least as potent as SP in eliciting MRGPRX2 internalization and (cross-)desensitization in skin MCs. These findings suggest that icatibant functions differently in primary versus transformed MCs, acting as a fully balanced ligand in the former by triggering not only degranulation but also receptor internalization and desensitization. Therefore, not only the ligand but also the MRGPRX2-expressing cell plays a decisive role in whether a ligand is balanced or biased. These findings are relevant to our understanding of icatibant’s clinical effects on edema and itch.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (BA-3769/4, 423161438)
- CSC and Charité (BA-3769/4, 423161438)
- ECARF (European Center for Allergy Research Foundation) (BA-3769/4, 423161438)
This publication has 62 references indexed in Scilit:
- Drug and Venom Allergy in MastocytosisImmunology and Allergy Clinics of North America, 2023
- Lactic acid suppresses MRGPRX2 mediated mast cell responsesCellular Immunology, 2021
- Non-IgE-Mediated Drug Hypersensitivity ReactionsCurrent Allergy and Asthma Reports, 2021
- Mast cells and IgE in defense against lethality of venoms: Possible “benefit” of allergyAllergo Journal, 2020
- Human Mast Cell Proteome Reveals Unique Lineage, Putative Functions, and Structural Basis for Cell AblationImmunity, 2020
- MrgX2 is a promiscuous receptor for basic peptides causing mast cell pseudo‐allergic and anaphylactoid reactionsPharmacology Research & Perspectives, 2019
- Novel MRGPRX2 antagonists inhibit IgE-independent activation of human umbilical cord blood-derived mast cellsJournal of Leukocyte Biology, 2019
- Mast cells signal their importance in health and diseaseJournal of Allergy and Clinical Immunology, 2018
- A single amino acid in MRGPRX2 necessary for binding and activation by pruritogensJournal of Allergy and Clinical Immunology, 2017
- LL-37-induced human mast cell activation through G protein-coupled receptor MrgX2International Immunopharmacology, 2017